Current Report Filing (8-k)
January 12 2021 - 4:31PM
Edgar (US Regulatory)
0001739940
false
0001739940
2021-01-06
2021-01-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) January 6, 2021
Cigna Corporation
(Exact name of registrant as specified in its
charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-38769
(Commission File Number)
|
82-4991898
(IRS Employer
Identification No.)
|
900 Cottage Grove Road
Bloomfield, Connecticut 06002
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(860) 226-6000
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[_] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.01
|
CI
|
New York Stock Exchange, Inc.
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [_]
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On January 6, 2021, the board of
directors (the “Board”) of Cigna Corporation (“Cigna”) appointed George Kurian as an independent member
of the Board, which appointment is effective March 1, 2021.
Mr. Kurian will participate in Cigna’s
non-employee director compensation program, amended and restated effective January 1, 2019, as described in Cigna’s proxy
statement for the 2020 annual meeting of shareholders, filed with the Securities and Exchange Commission (the “SEC”)
on March 13, 2020. A copy of the non-employee director compensation program has been filed as Exhibit 10.17 to Cigna’s Annual
Report on Form 10-K for the year ended December 31, 2019.
There is no arrangement or understanding
between Mr. Kurian and any other person pursuant to which Mr. Kurian was selected as a director. Mr. Kurian has no direct or indirect
material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities
Exchange Act of 1934, as amended.
The Company will file an amended
Form 8-K to disclose Mr. Kurian’s committee assignments once determined.
A copy of Cigna's press release
announcing the appointment of Mr. Kurian is attached to this report as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release dated January 12, 2021
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Cigna Corporation
|
Date: January 12, 2021
|
By:
|
/s/ Nicole S. Jones
|
|
|
Nicole S. Jones
|
|
|
Executive Vice President and
General Counsel
|
|
|
|
|
|
|
Cigna (NYSE:CI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cigna (NYSE:CI)
Historical Stock Chart
From Sep 2023 to Sep 2024